Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company’s leading position is already being tested by Novo Nordisk’s GLP-1 weight loss pill.
Source: https://www.fool.com/investing/2026/01/23/forget-eli-lilly-b…
An upcoming spinoff could unlock tremendous value for investors in high-yielder Kraft Heinz. Kimberly-Clark’s planned merger with Johnson & Johnson spinoff Kenvue may bode well for future dividend growth and price appreciation.
Cannabis stocks surged Friday following reports President Donald Trump could soon reclassify marijuana as a less dangerous substance.
Artemis is a long-term NASA program, so it seems likely that some companies involved will benefit for some time. Artemis contracts could move the needle more on smaller companies’ financials than on those of the massive prime contractors.
